ArticleInvestigative ophthalmology & visual science2025
Central Bouquet Hemorrhages in Retinal Vein Occlusion: A Distinct Pathway to Macular Atrophy.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To characterize central bouquet hemorrhages (CBHs) in retinal vein occlusion (RVO) and evaluate their association with long-term visual and anatomical outcomes, in particular macular atrophy. This is a retrospective longitudinal cohort study of 403 treatment-naïve eyes with RVO (mean age, 62.9 ± 15.4 years; 59% male). Methods: CBH was identified on spectral-domain optical coherence tomography as vertically oriented light-absorbing masses centered at the fovea, above the external limiting membrane. Clinical characteristics, imaging findings, and intravitreal treatment frequency were compared between eyes with and without CBH. Baseline and longitudinal visual acuity analyzed with multivariable regression models, the prevalence of CBH-related features, and the cumulative incidence and predictors of macular atrophy assessed with Cox regression models were assessed. Results: CBH were observed in 28% of eyes (n = 111) at baseline. Affected eyes were older, had more systemic vascular comorbidities, and presented with more severe macular edema, peripapillary hemorrhages, and cotton-wool spots (all P < 0.001). Ischemic markers-including arteriolar paracentral acute middle maculopathy (P = 0.04) and increased ischemic index on fluorescein angiography (P = 0.02)-were more common in CBH eyes. Over time, CBH reabsorbed, often leaving a plaque-like RPE thickening, which progressed to outer retinal atrophy in 69% of cases over 36 months. Severe cystoid macular edema and full-thickness macular holes were also common. CBH was independently associated with worse baseline visual acuity (β = 0.09 logMAR; 95% confidence interval [CI], 0.01-0.18; P = 0.04) and slower visual recovery (β for CBH × Time = -0.002 logMAR/month; P < 0.001). Intravitreal treatments reduced the risk of macular atrophy (hazard ratio, 0.28; 95% CI, 0.08-0.96; P = 0.04), and each additional injection conferred a protective effect (hazard ratio, 0.96; 95% CI, 0.93-0.99; P = 0.02). Conclusions: CBH represents a characteristic hemorrhagic manifestation in RVO, likely reflecting the localized effects of elevated venous pressure and macular ischemia that contribute to structural disruption and poor visual outcomes. Its presence warrants close monitoring and sustained treatment to mitigate long-term retinal damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.